Clinical Trial Update: Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of mocetinostat with durvalumab in advanced solid tumors and NSCLC was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Mocetinostat (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-04-06